PuSH - Publication Server of Helmholtz Zentrum München: Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis "

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Justet, A* ; Wagner, D.E.* ; Königshoff, M.* ; Alsafadi, H.N.* ; Mitash, N.* ; Justet, A.* ; Hu, Q.* ; Pineda, R.* ; Staab-Weijnitz, C.A.* ; Korfei, M.* ; Mutze, K.* ; Costa, R.* ; Bolukbas, D.* ; Stegmayr, J.* ; Skronska-Wasek, W.* ; Ota, C.* ; Baarsma, H.A.* ; Sembrat, J.* ; Hilgendorff, A.* ; Günther, A.* ; Chambers, R.C.* ; de Langhe, S.* ; Kaminski, N.* ; Lehmann, M.* ; Eickelberg, O.*

Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis "

(2024)

Abstract
Metrics
Extra information

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease characterized by excessive extracellular matrix (ECM) deposition. Current IPF therapies slow disease progression but do not stop or reverse it. The (myo)fibroblasts are thought to be the main cellular contributors to excessive ECM production in IPF. Here we report that fibrotic AT2 cells regulate production and crosslinking of ECM via the co-transcriptional activator YAP. YAP leads to increase expression of Lysyloxidase (LOX) and subsequent LOX mediated crosslinking by fibrotic AT2 cells. Pharmacological YAP inhibition reverses fibrotic AT2 cell reprogramming and LOX expression in experimental lung fibrosis in vivo and in human fibrotic tissue ex vivo. We thus identify YAP-TEAD/LOX inhibition in AT2 cells as a promising potential new therapy for IPF patients.